New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
OBJECTIVE
This overview reviews the impact of second-generation antipsychotics on less frequently researched outcomes such as medication-adherence behaviour, quality of life, and subjective tolerability in patients with schizophrenia.


METHODS
We selectively reviewed recent literature and considered our own research and experiences in the field.


RESULTS
Most published studies about second-generation antipsychotics have dealt with issues related to efficacy and safety. So far, not many studies have focused on effectiveness in terms of such important outcomes as medication-adherence behaviour, quality of life, subjective tolerability, and overall satisfaction with treatment. Although most studies are inconclusive and their results are inconsistent--which has to do with several design and methodological limitations--there seems, on balance, to be a trend indicating superiority of second-generation, compared with first-generation, antipsychotics in improving medication-adherence behaviour and quality of life. The trend toward more favourable subjective tolerability and less frequent neuroleptic dysphoria seems to be relatively stronger.


CONCLUSIONS
At present, the state of the art can only indicate a more favourable trend for second-generation antipsychotics in regard to improving medication adherence behaviour, quality of life, and subjective tolerability. It is surprising that such important outcomes, which are likely the defining factors in the superiority of second-generation antipsychotics, have not received adequate research attention. Well-designed, controlled, and adequately powered studies are urgently needed before any firm conclusions can be reached.
Awad
A George
AG
University of Toronto, Institute of Medical Science, Ontario. gawad@hrrh.on.ca
Voruganti
Lakshmi N P
LN
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000145:classification; D001294:Attitude to Health; D004361:Drug Tolerance; D006801:Humans; D019964:Mood Disorders / Q000139:chemically induced; D010349:Patient Compliance; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents